{"id":"https://openalex.org/W2103487864","doi":"https://doi.org/10.1111/dme.12301","title":"The potential risks of pancreatitis and pancreatic cancer with GLP\u20101\u2010based therapies are far outweighed by the proven and potential (cardiovascular) benefits","display_name":"The potential risks of pancreatitis and pancreatic cancer with GLP\u20101\u2010based therapies are far outweighed by the proven and potential (cardiovascular) benefits","alternate_titles":[],"publication_year":2013,"publication_date":"2013-09-16","ids":{"openalex":"https://openalex.org/W2103487864","doi":"https://doi.org/10.1111/dme.12301","mag":"2103487864","pmid":"https://pubmed.ncbi.nlm.nih.gov/24073725"},"language":"en","primary_location":{"id":"doi:10.1111/dme.12301","doi":"https://doi.org/10.1111/dme.12301","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dme.12301","pdf_url":null,"source":{"id":"https://openalex.org/S72944096","display_name":"Diabetic Medicine","issn_l":"0742-3071","issn":["0742-3071","1096-9136","1464-5491"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic Medicine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2103487864"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071127270","display_name":"Robert E. J. Ryder","orcid":"https://orcid.org/0000-0003-4424-355X","observed_orcids":["https://orcid.org/0000-0003-4424-355X"]},"institutions":[{"id":"https://openalex.org/I2799802789","display_name":"Birmingham City Hospital","ror":"https://ror.org/02smq5q54","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799630439","https://openalex.org/I2799802789"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"R. E. J. Ryder","raw_affiliation_strings":["Department of Diabetes and Endocrinology, City Hospital, Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Diabetes and Endocrinology, City Hospital, Birmingham, UK","institution_ids":["https://openalex.org/I2799802789"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5071127270"],"corresponding_institution_ids":["https://openalex.org/I2799802789"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":null,"fwci":0.7736,"has_fulltext":false,"cited_by_count":48,"citation_normalized_percentile":{"value":0.59038558,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"30","issue":"10","first_page":"1148","last_page":"1155"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9340000152587891},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.968999981880188},{"id":"https://openalex.org/keywords/pancreatitis","display_name":"pancreatitis","score":0.9269999861717224},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.5879999995231628},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5910000205039978},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.5289999842643738},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.6489999890327454},{"id":"https://openalex.org/keywords/benefit-risk-balance","display_name":"benefit-risk balance","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9279327988624573},{"id":"https://openalex.org/C2775967933","wikidata":"https://www.wikidata.org/wiki/Q1527888","display_name":"Pancreatitis","level":2,"score":0.8819524049758911},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.6803381443023682},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6283608675003052},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5623638033866882},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5366978049278259},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4634990394115448},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.4562051296234131},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.43292129039764404},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.4306701421737671},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4164494276046753},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3723679184913635},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3308582901954651},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3256242275238037},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.32106178998947144},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23238906264305115}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000067758","descriptor_name":"Glucagon-Like Peptide-2 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010195","descriptor_name":"Pancreatitis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D010195","descriptor_name":"Pancreatitis","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014688","descriptor_name":"Venoms","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018579","descriptor_name":"Patient Selection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/dme.12301","doi":"https://doi.org/10.1111/dme.12301","is_oa":false,"landing_page_url":"https://doi.org/10.1111/dme.12301","pdf_url":null,"source":{"id":"https://openalex.org/S72944096","display_name":"Diabetic Medicine","issn_l":"0742-3071","issn":["0742-3071","1096-9136","1464-5491"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic Medicine","raw_type":"journal-article"},{"id":"pmid:24073725","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24073725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetic medicine : a journal of the British Diabetic Association","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W1515933387","https://openalex.org/W1547073044","https://openalex.org/W1565699562","https://openalex.org/W1970516435","https://openalex.org/W1970638723","https://openalex.org/W1976109615","https://openalex.org/W1987548551","https://openalex.org/W2002189205","https://openalex.org/W2005815117","https://openalex.org/W2006259799","https://openalex.org/W2008609411","https://openalex.org/W2015028576","https://openalex.org/W2027276740","https://openalex.org/W2031627672","https://openalex.org/W2036471275","https://openalex.org/W2037432865","https://openalex.org/W2043764971","https://openalex.org/W2054925541","https://openalex.org/W2058683641","https://openalex.org/W2060216485","https://openalex.org/W2063489619","https://openalex.org/W2064130493","https://openalex.org/W2070710390","https://openalex.org/W2071090755","https://openalex.org/W2091122818","https://openalex.org/W2094195067","https://openalex.org/W2098008729","https://openalex.org/W2098268725","https://openalex.org/W2103815175","https://openalex.org/W2106971761","https://openalex.org/W2111640589","https://openalex.org/W2112981414","https://openalex.org/W2120832225","https://openalex.org/W2123946565","https://openalex.org/W2127854619","https://openalex.org/W2134141467","https://openalex.org/W2135141378","https://openalex.org/W2136259411","https://openalex.org/W2137982063","https://openalex.org/W2138897693","https://openalex.org/W2140682563","https://openalex.org/W2144397405","https://openalex.org/W2151848850","https://openalex.org/W2155234088","https://openalex.org/W2157869836","https://openalex.org/W2158778171","https://openalex.org/W2163153907","https://openalex.org/W2164352118","https://openalex.org/W2164535707","https://openalex.org/W2183267200","https://openalex.org/W2185663072","https://openalex.org/W4212850438"],"related_works":["https://openalex.org/W2990539453","https://openalex.org/W2885769996","https://openalex.org/W2157501692","https://openalex.org/W3006785779","https://openalex.org/W2592954074","https://openalex.org/W2607170437","https://openalex.org/W4411291272","https://openalex.org/W2009969219","https://openalex.org/W2155500946"],"abstract_inverted_index":{"Recent":[0],"suggestions":[1],"that":[2,42,183,190],"glucagon-like":[3],"peptide-1":[4],"(GLP-1)-based":[5],"therapies":[6,48,77,117,133],"could":[7,49,121],"cause":[8],"pancreatitis,":[9],"and":[10,29,64,78,94,197,233],"even":[11],"pancreatic":[12,95],"cancer,":[13],"are":[14,23,30,58,97],"based":[15],"on:":[16],"ANIMAL":[17],"STUDIES:":[18],"The":[19,66,89,180],"worrying":[20],"histological":[21],"changes":[22],"not":[24,71,135],"reproduced":[25],"in":[26,54,252],"all":[27],"studies":[28,69],"unexpectedly":[31],"variable":[32],"with":[33,46,131,175,207,257],"different":[34],"GLP-1-based":[35,47,76,116,132,255],"therapies.":[36],"AN":[37],"OBSERVATIONAL":[38],"STUDY:":[39],"Singh's":[40],"findings":[41,112],"pancreatitis":[43,61,93,138,231],"is":[44,185,250],"doubled":[45],"relate":[50],"to":[51,60,99,102],"their":[52],"use":[53],"obese":[55],"patients":[56,152],"who":[57],"prone":[59],"risk":[62,157,232],"factors--gallstones":[63],"hypertriglyceridaemia.":[65],"other":[67,123],"observational":[68],"do":[70,134],"find":[72,136],"an":[73],"association":[74],"between":[75],"pancreatitis.":[79],"US":[80],"FOOD":[81],"AND":[82],"DRUG":[83],"ADMINISTRATION":[84],"ADVERSE":[85],"EVENT":[86],"REPORTING":[87],"SYSTEM:":[88],"increased":[90,137],"reports":[91],"of":[92,141,158,192,230,237,248,254],"cancer":[96],"likely":[98],"be":[100,205],"attributable":[101],"'notoriety":[103],"bias'.":[104],"A":[105],"STUDY":[106],"OF":[107],"ORGAN":[108],"DONOR":[109],"PANCREASES:":[110],"Butler's":[111],"for":[113,170],"those":[114,119],"on":[115],"vs.":[118],"not,":[120],"have":[122],"explanations.":[124],"Meanwhile:":[125],"META":[126],"ANALYSIS:":[127],"Randomized":[128],"control":[129,176],"trials":[130,145,217,225],"risk.":[139],"Meta-analysis":[140],"53":[142],"randomized":[143,215],"controlled":[144,216],"including":[146],"20":[147],"212":[148],"dipeptidyl":[149,171,201],"peptidase-4":[150,172,202],"inhibitor-treated":[151],"found":[153],"a":[154,188],"significantly":[155],"reduced":[156,208],"major":[159],"adverse":[160],"cardiovascular":[161,209,214],"events":[162],"[odds":[163],"ratio":[164],"0.689":[165],"(0.528-0.899),":[166],"P":[167],"=":[168],"0.006]":[169],"inhibitors":[173],"compared":[174],"subjects.":[177],"CARDIOVASCULAR":[178],"RISK:":[179],"evidence":[181,249],"suggests":[182],"there":[184],"more":[186],"than":[187],"possibility":[189],"some":[191,200],"the":[193,228,235,246],"GLP-1":[194],"receptor":[195],"agonists,":[196],"possibly":[198],"also":[199],"inhibitors,":[203],"may":[204],"associated":[206],"events.":[210],"Eight":[211],"ongoing":[212],"long-term":[213],"will":[218],"report":[219],"from":[220],"September":[221],"2013":[222],"onwards.":[223],"These":[224],"should":[226,242],"resolve":[227],"issue":[229],"substantiate":[234],"extent":[236],"benefit.":[238],"CONCLUSION:":[239],"Whilst":[240],"we":[241],"remain":[243],"vigilant,":[244],"currently":[245],"balance":[247],"strongly":[251],"support":[253],"therapy,":[256],"benefits":[258],"far":[259],"outweighing":[260],"potential":[261],"risks.":[262]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2103487864","counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
